Walleye Trading’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $33.1K | Sell |
100
-500
| -83% | -$170K | ﹤0.01% | 3781 |
|
|
2025
Q4 | $239K | Hold |
600
| – | – | ﹤0.01% | 3298 |
|
|
2025
Q3 | $274K | Sell |
600
-1,200
| -67% | -$489K | ﹤0.01% | 3165 |
|
|
2025
Q2 | $587K | Sell |
1,800
-1,700
| -49% | -$470K | ﹤0.01% | 2542 |
|
|
2025
Q1 | $945K | Sell |
3,500
-2,100
| -38% | -$540K | ﹤0.01% | 2098 |
|
|
2024
Q4 | $1.32M | Sell |
5,600
-1,000
| -15% | -$263K | ﹤0.01% | 1962 |
|
|
2024
Q3 | $1.82M | Buy |
6,600
+2,100
| +47% | +$547K | ﹤0.01% | 1745 |
|
|
2024
Q2 | $1.09M | Sell |
4,500
-13,700
| -75% | -$2.16M | ﹤0.01% | 2004 |
|
|
2024
Q1 | $2.72M | Buy |
18,200
+2,200
| +14% | +$367K | 0.01% | 1533 |
|
|
2023
Q4 | $3.06M | Buy |
16,000
+2,700
| +20% | +$460K | 0.01% | 1586 |
|
|
2023
Q3 | $2.36M | Buy |
13,300
+2,300
| +21% | +$439K | 0.01% | 1662 |
|
|
2023
Q2 | $2.09M | Sell |
11,000
-10,500
| -49% | -$2.08M | 0.01% | 1619 |
|
|
2023
Q1 | $4.31M | Buy |
21,500
+2,400
| +13% | +$504K | 0.01% | 1153 |
|
|
2022
Q4 | $4.54M | Sell |
19,100
-38,200
| -67% | -$8.15M | 0.01% | 1139 |
|
|
2022
Q3 | $11.5M | Buy |
57,300
+28,500
| +99% | +$5.44M | 0.03% | 557 |
|
|
2022
Q2 | $4.2M | Buy |
28,800
+3,000
| +12% | +$426K | 0.01% | 1142 |
|
|
2022
Q1 | $4.21M | Buy |
25,800
+25,300
| +5,060% | +$3.85M | 0.01% | 1106 |
|
|
2021
Q4 | $85K | Buy |
+500
| New | +$92.9K | ﹤0.01% | 4460 |
|
|
2021
Q3 | – | Sell |
-45,900
| Closed | -$7.78M | – | 5150 |
|
|
2021
Q2 | $7.78M | Buy |
45,900
+41,600
| +967% | +$6.09M | 0.03% | 559 |
|
|
2021
Q1 | $607K | Buy |
4,300
+4,100
| +2,050% | +$617K | ﹤0.01% | 2428 |
|
|
2020
Q4 | $26K | Sell |
200
-27,700
| -99% | -$3.7M | ﹤0.01% | 4342 |
|
|
2020
Q3 | $4.06M | Buy |
27,900
+21,000
| +304% | +$2.98M | 0.02% | 681 |
|
|
2020
Q2 | $1.02M | Sell |
6,900
-9,000
| -57% | -$1.21M | 0.01% | 1649 |
|
|
2020
Q1 | $1.73M | Sell |
15,900
-7,600
| -32% | -$877K | 0.01% | 941 |
|
|
2019
Q4 | $2.71M | Buy |
23,500
+19,300
| +460% | +$1.92M | 0.02% | 983 |
|
|
2019
Q3 | $338K | Buy |
4,200
+3,600
| +600% | +$285K | ﹤0.01% | 2480 |
|
|
2019
Q2 | $44K | Sell |
600
-17,500
| -97% | -$1.34M | ﹤0.01% | 3581 |
|
|
2019
Q1 | $1.69M | Buy |
18,100
+13,700
| +311% | +$1.15M | 0.01% | 1224 |
|
|
2018
Q4 | $321K | Buy |
4,400
+2,300
| +110% | +$177K | ﹤0.01% | 2915 |
|
|
2018
Q3 | $184K | Sell |
2,100
-1,900
| -48% | -$191K | ﹤0.01% | 3823 |
|
|
2018
Q2 | $394K | Buy |
+4,000
| New | +$397K | ﹤0.01% | 3053 |
|
Other funds holding ALNY
VPM
VCM
Walleye Trading's ALNY Position: Q1 2026 in Review
Walleye Trading reduced its Alnylam Pharmaceuticals (ALNY) stake by 34% in Q1 2026, selling an estimated $987K and leaving 5,756 shares worth $1.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1746.
Walleye Trading first reported a position in ALNY in Q2 2015 and has held it in 25 quarters since. The position peaked at $5.65M in Q3 2022. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.
- Walleye Trading held 5,756 shares of Alnylam Pharmaceuticals worth $1.9M as of Q1 2026.
- Walleye Trading sold 2,901 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $987K.
- Alnylam Pharmaceuticals made up ﹤0.01% of Walleye Trading's portfolio in Q1 2026, its #1746 holding.
- Walleye Trading first reported a position in Alnylam Pharmaceuticals in Q2 2015 and has held it in 25 quarters since.
- Walleye Trading's Alnylam Pharmaceuticals position peaked at $5.65M in Q3 2022.
- 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.
Based on Walleye Trading's 13F filing for Q1 2026, filed 11 May 2026.